RXRX
Recursion Pharmaceuticals, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 103 | -2 | 264.97M | $972.27M | +5 | −6 |
| Q1 2026 | 107 | +3 | 243.54M | $747.81M | +9 | −7 |
| Q4 2025 | 104 | +2 | 261.79M | $1.07B | +4 | −1 |
| Q3 2025 | 16 | -2 | 173.92M | $848.75M | — | −3 |
| Q2 2025 | 16 | 0 | 153.65M | $777.46M | — | — |
| Q1 2025 | 13 | +3 | 87.35M | $462.12M | +3 | — |
| Q4 2024 | 10 | 0 | 84.02M | $567.97M | — | — |
| Q3 2024 | 9 | +2 | 69.10M | $455.38M | +2 | — |
| Q2 2024 | 7 | — | 63.72M | $477.87M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | ARK Investment Management ✦ | 28.14M | — | $211.07M | 1.9% | n/c | 1 | SEC ↗ |
| 2 | Baillie Gifford ✦ | 26.59M | — | $199.42M | 0.2% | n/c | 1 | SEC ↗ ×4 |
| 3 | Geode Capital Management ✦ (passive) | 4.78M | — | $35.83M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Norges Bank ✦ (passive) | 1.95M | — | $14.60M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Two Sigma Investments ✦ | 1.43M | — | $10.70M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 745.08K | — | $5.59M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 7 | T. Rowe Price ✦ | 88.11K | — | $661,000 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 333 holders, 334.81M shares, $1.02B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 50.00K sh · $242,000
Director · 25.00K sh · $125,000
Officer, Director · 22.41K sh · $78,822
Director · 30.00K sh · $100,200
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology